Elevated Tumour Markers Prior to Complete Tumour Removal in Patients with Pseudomyxoma Peritonei Predict Early Recurrence

Overview

Journal Colorectal Dis

Specialty Gastroenterology

Date 2005 Jun 4

PMID 15932563

Citations 22

Authors

F Alexander-Sefre

K Chandrakumaran

S Banerjee

R Sexton

J M Thomas

B Moran

Affiliations

Soon will be listed here.

Abstract

Objective: To assess the potential value of pre-operative CEA, CA 125 and CA 19-9 in identifying Pseudomyxoma peritonei (PMP) patients at risk of recurrence following complete cytoreductive surgery and intraperitoneal chemotherapy.

Method: Between March 1996 and October 2001, 35 patients, with documented pre-operative tumour marker measurements, underwent complete cytoreduction. Outcome in the 32 survivors was recorded.

Results: Median age was 53 years (range: 32-74). There were 17[53%] females. In 9/32[28%] all tumour markers were normal. The most common abnormality was elevated CEA level in 14/32[44%]. Median follow up was 23 months (range: 11-74). Recurrence was detected in 8/32[25%]. The 2-year recurrence free interval was 53% in those with elevated CEA compared with 94% with normal CEA. The 2-year disease free intervals were 100% in 9 patients with normal preop markers compared with 66% for the group with at least one abnormal marker.

Conclusion: PMP patients with elevated CEA, or more than one abnormal serum tumour maker, are at risk of developing recurrent disease.

Citing Articles

Pseudomyxoma peritonei: The struggle of a lifetime and the hope of a cure - a rare diagnosis with review of the literature.

Askar A, Arpat A, Durgun V North Clin Istanb. 2024; 11(3):261-268.

PMID: 39005750 PMC: 11237824. DOI: 10.14744/nci.2023.50374.

Appendiceal Mucinous Neoplasms: From Clinic to Pathology and Prognosis.

Gonzalez Bayon L, Roman L, Lominchar P Cancers (Basel). 2023; 15(13).

PMID: 37444536 PMC: 10340652. DOI: 10.3390/cancers15133426.

[Surgical treatment for recurrent intra-abdominal mucinous neoplasms].

Leebmann H, Blaj S, Piso P Chirurgie (Heidelb). 2023; 94(10):845-849.

PMID: 37432477 DOI: 10.1007/s00104-023-01925-7.

Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei.

Patrick-Brown T, Mohamed F, Thrower A, Torgunrud A, Cosyns S, Canbay E Pleura Peritoneum. 2023; 8(1):1-9.

PMID: 37020469 PMC: 10067554. DOI: 10.1515/pp-2022-0200.

Overall Survival is More Closely Associated with Peritoneal than Primary Appendiceal Pathological Grade in Pseudomyxoma Peritonei with Discordant Pathology.

Memon A, Godbole C, Cecil T, Dayal S, Moran B, Tzivanakis A Ann Surg Oncol. 2021; 29(4):2607-2613.

PMID: 34731401 DOI: 10.1245/s10434-021-10994-z.